Metabonomics research on lung tissue of rats with acute exacerbation of chronic obstructive pulmonary disease treated with mineral Chinese medicine Chloriti Lapis.
10.19540/j.cnki.cjcmm.20210308.202
- Author:
Sheng-Jin LIU
1
;
Yu-Lu MA
1
;
Fang FANG
1
;
Rui WANG
1
;
Wen-Guo YANG
1
;
Chen-Xiao SHAN
1
;
Yong BIAN
1
;
Hui YAN
1
;
Zhi-Jie ZHANG
2
;
AO WULIJI
3
;
Jin-Ao DUAN
1
Author Information
1. Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization,National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine,State Administration of Traditional Chinese Medicine Key Laboratory of Chinese Medicinal Resources Recycling Utilization,School of Pharmacy,Nanjing University of Chinese Medicine Nanjing 210023,China.
2. Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences Beijing 100700,China.
3. Inner Mongolia University for Nationalities Tongliao 028000,China.
- Publication Type:Journal Article
- Keywords:
Chloriti Lapis;
chronic obstructive pulmonary disease(COPD);
lung tissue;
metabonomics;
mineral Chinese medicine(MCM)
- MeSH:
Animals;
Lung;
Medicine, Chinese Traditional;
Metabolomics;
Minerals;
Pulmonary Disease, Chronic Obstructive;
Rats
- From:
China Journal of Chinese Materia Medica
2021;46(12):3133-3143
- CountryChina
- Language:Chinese
-
Abstract:
To study the effect of mineral Chloriti Lapis on pulmonary metabolites and metabolic pathways in lung tissues of rats with acute exacerbation of chronic obstructive pulmonary disease(AECOPD). The AECOPD rat model of phlegm heat syndrome was replicated by the method of smoking combined with Klebsiella pneumoniae infection. Except for using UPLC-Q-TOF-MS analysis, SPSS 18.0, SIMCA 13.0 and other software were also used for statistical analysis. Through literature search and online database comparison, the differential metabolites were identified, and the possible metabolic pathways were analyzed. After 15 days of administration, PLS-DA analysis was carried out on lung tissue samples of rats in each group. The results showed that the metabolic profiles of lung tissues of rats in each group could be well separated, which indicated that Chloriti Lapis and aminophylline had significant intervention effect on the lung metabolic profile of rats with AECOPD. Moreover, the metabolic profile of Chloriti Lapis group was closer to that of control group, and the intervention effect was better than that of aminophylline group. As a result, 15 potential differential metabolites were identified: phytosphingosine, sphinganine, tetradecanoylcarnitine, L-palmitoylcarnitine, elaidic carnitine, lysoPC[18∶2(9Z,12Z)], lysoPC(16∶0), lysoPC[18∶1(9Z)], lysoPC(18∶0), stearic acid, lysoPC(15∶0), arachidonic acid, docosapentaenoic acid, linoleic acid and palmitic acid. Among them, Chloriti Lapis could significantly improve the levels of 10 differential metabolites of phytosphingosine, tetradecanoylcarnitine, L-palmitoylcarnitine, elaidic carnitine, lysoPC[18∶2(9Z,12Z)], lysoPC(16∶0), lysoPC[18∶1(9Z)], stearic acid, lysoPC(15∶0), and palmitic acid(P<0.05). The intervention effect of Chloriti Lapis group was better than that of aminophylline group. Analysis of metabolic pathways showed that there were 8 possible metabolic pathways that could be affected, and three of the most important metabolic pathways(pathway impact>0.1) were involved: linoleic acid metabolism, arachidonic acid metabolism, and sphingolipid metabolism. Chloriti Lapis had obvious intervention effects on lung tissue-related metabolites and metabolic pathways in rats with AECOPD, and the effect was better than that of aminophyllinne.
